buprenorphine


Also found in: Thesaurus, Medical, Wikipedia.

bu·pre·nor·phine

 (byo͞o′prə-nôr′fēn′)
n.
A semisynthetic opioid drug, C29H41NO4, used usually in its hydrochloride form as an analgesic and, in combination with naloxone, for long-term treatment of addiction to opioids such as heroin.
[bu(tyl) + pr(opyl) + en(do-) or (eth)en(e) + (m)orphine.]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

buprenorphine

(bjuːˈprɛnɔːfiːn)
n
(Medicine) an opiate used medicinally as a powerful analgesic
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014
Translations

buprenorphine

n buprenorfina
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
Mentioned in ?
References in periodicals archive ?
21, 2019 (HealthDay News) -- Using buprenorphine to treat opioid use disorder (OUD) may increase adherence to treatments for other chronic conditions, according to a study published in the September issue of Medical Care.
Taking Buprenorphine for Opioid Use Disorder May Up Other Med Compliance; Findings seen among those taking buprenorphine and any of five other drug classes
The lawmakers should also call for introducing a key component of drug dependency treatment which is buprenorphine. The estimates of drug addicts in Pakistan has large variability and ranges from 100,000 to half a million people.
Drug rehabilitation
Researchers combined data from 13.4 million outpatient visits using the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey, and analyzed how often buprenorphine was prescribed from 2012 to 2015.
Opioid deaths are at epidemic levels in the U.S., making it essential for people struggling with opioid use disorder (OUD) to have access to effective treatments, including drugs that doctors can prescribe from the office setting
BioDelivery Sciences International shared how its scientific investments for BELBUCA throughout 2019, including clinical trials, publications, and medical education initiatives align with the recommendations regarding buprenorphine from the recently released Pain Management Best Practices Inter-Agency Task Force's final report which proposes best practices for managing chronic and acute pain.
BioDelivery Sciences expands upon report from Pain Management Task Force
(3,4) Central to addressing the opioid crisis is improving access to evidence-based medications for the treatment for OUD--methadone, buprenorphine, and naltrexone.
County-level access to opioid use disorder medications in medicare Part D (2010-2015)
FDA issued a final guidance, "Opioid Use Disorder: Developing Buprenorphine Depot Products for Treatment," which outlines the FDA's current thinking about drug development and trial design issues relevant to the study of buprenorphine depot products, such as modified-release products for injection or implantation.
FDA finalizes policy on new buprenorphine treatments for opioid use disorder
Evaluation of the thermal antinociceptive effects and pharmacokinetics after intramuscular administration of buprenorphine hydrochloride to cockatiels (Nymphicus hollandicus).
Evaluation of the thermal antinociceptive effects and pharmacokinetics after intramuscular administration of buprenorphine hydrochloride to cockatiels (Nymphicus hollandicus)
Pharmaceutical company Mylan NV (NASDAQ:MYL) revealed on Friday the availability of Buprenorphine and Naloxone Sublingual Film in 8 mg/2 mg and 12 mg/3 mg in the US.
Mylan unveils generic Suboxone Sublingual Film for treating opioid dependence
Specifically, in rural Maryland, physicians used telemedicine to provide buprenorphine treatment for OUD at a treatment center in August 2015.
Rural teleorescribing for opioid use disorder shows success
This article reviews MAT with buprenorphine; other MAT options include methadone and naltrexone.
Buprenorphine to treat opioid use disorder: A practical guide
High relapse rates typically occur after standard detoxification, (11,13,18) which are reported to reach [greater than or equal to] 50% 1 to 2 months after discontinuation of buprenorphine maintenance.
Managing the Opioid Use Disorder Crisis

Dictionary browser ?
Full browser ?